JP2023536636A5 - - Google Patents

Info

Publication number
JP2023536636A5
JP2023536636A5 JP2023507701A JP2023507701A JP2023536636A5 JP 2023536636 A5 JP2023536636 A5 JP 2023536636A5 JP 2023507701 A JP2023507701 A JP 2023507701A JP 2023507701 A JP2023507701 A JP 2023507701A JP 2023536636 A5 JP2023536636 A5 JP 2023536636A5
Authority
JP
Japan
Prior art keywords
group
therapy
immunomodulatory
status
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044240 external-priority patent/WO2022031630A1/en
Publication of JP2023536636A publication Critical patent/JP2023536636A/ja
Publication of JP2023536636A5 publication Critical patent/JP2023536636A5/ja
Pending legal-status Critical Current

Links

JP2023507701A 2020-08-03 2021-08-02 腫瘍の分類及び応答性の予測 Pending JP2023536636A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060321P 2020-08-03 2020-08-03
US63/060,321 2020-08-03
US202063121837P 2020-12-04 2020-12-04
US63/121,837 2020-12-04
US202163173180P 2021-04-09 2021-04-09
US63/173,180 2021-04-09
PCT/US2021/044240 WO2022031630A1 (en) 2020-08-03 2021-08-02 Classifying tumors and predicting responsiveness

Publications (2)

Publication Number Publication Date
JP2023536636A JP2023536636A (ja) 2023-08-28
JP2023536636A5 true JP2023536636A5 (https=) 2024-08-13

Family

ID=80118483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507701A Pending JP2023536636A (ja) 2020-08-03 2021-08-02 腫瘍の分類及び応答性の予測

Country Status (8)

Country Link
US (1) US20230296584A1 (https=)
EP (1) EP4188330A4 (https=)
JP (1) JP2023536636A (https=)
KR (1) KR20230058410A (https=)
CN (1) CN116322639A (https=)
AU (1) AU2021322092A1 (https=)
CA (1) CA3188358A1 (https=)
WO (1) WO2022031630A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
CN115436636A (zh) * 2022-11-08 2022-12-06 济南市中心医院 连接粘附分子样蛋白jaml在结直肠癌中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843417C (en) * 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
WO2014080381A1 (en) * 2012-11-26 2014-05-30 Ecole Polytechnique Federale De Lausanne (Epfl) Colorectal cancer classification with differential prognosis and personalized therapeutic responses
GB201512869D0 (en) * 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2018132916A1 (en) * 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3727368A4 (en) * 2017-12-19 2021-10-20 Abraxis BioScience, LLC METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY
EP3788369A1 (en) * 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN110927389B (zh) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途

Similar Documents

Publication Publication Date Title
US11091809B2 (en) Molecular diagnostic test for cancer
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US10260097B2 (en) Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
US20240282449A1 (en) Methods and systems for machine learning analysis of inflammatory skin diseases
US20220399116A1 (en) Systems and methods for assessing a bacterial or viral status of a sample
Ren et al. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance
US20230340601A1 (en) Transcriptome Analysis For Treating Inflammation
AU2012261820A1 (en) Molecular diagnostic test for cancer
US20250273295A1 (en) Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
US20240219385A1 (en) Molecular signatures of long-term covid-19 and treatment thereof
Natividad et al. Human conjunctival transcriptome analysis reveals the prominence of innate defense in Chlamydia trachomatis infection
Higham et al. Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease
JP2023536636A5 (https=)
US20240093318A1 (en) Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes
CN107523626A (zh) 一组用于活动性肺结核无创诊断的外周血基因标记物
US20240084391A1 (en) Diagnostic Methods and Methods of Treatment of Ovarian Cancer
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy
JP2022061491A (ja) 慢性副鼻腔炎の患者を分類するためのデータの取得方法、およびその利用
Seligmann et al. Molecular gene expression testing to identify Alzheimer’s disease with high accuracy from fingerstick blood
US20260117297A1 (en) Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases
Colbey et al. Key viral immune genes and pathways identify elite athletes with URS
US20250197946A1 (en) Biomarkers for colorectal neoplasia
Argyriou et al. POS0069 SYNOVIAL IMMUNE CELLS EXHIBIT A TYPE I IFN GENE SIGNATURE IN ACPA-NEGATIVE RHEUMATOID ARTHRITIS
Zhang et al. The role of SP100 in tumour immune microenvironment and prognosis of head and neck squamous cell carcinoma
Du Diagnosing and predicting clinical outcomes based on computational methods for immune microenvironment patterns: two examples